Market Cap
$4.2B
LIVN
LivaNova PLC
$75.07 ▲ +0.50%
Prev close $74.70Market cap$4.2B
ConsensusStrong Buy
12-mo target$89.10 (+18.7%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10) Healthcare & Medical Devices
Snapshot
The big-picture read on LIVN right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (81%)
Insider Activity
$0.00 buy / $1.0M sell
Insider Net $
-$1.0M
Social Sentiment
50° Neutral
SEC Reports
5
Price chart 30d -7.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 15, 2026 Insider
Sep 14, 2026 SEC Liddy Anne M. was granted 6,291 shares
Chief Legal Officer
Two LivaNova directors sold a combined $460K in open-market sales over a one-week window, with Bianchi Francesco selling
CLUSTER — Impact 2/10
Sep 10, 2026 Insider
Bianchi Francesco sold 3,500 shares
Director @ $78.01 ($273.0K)
Sep 4, 2026 Insider
Aug 5, 2026 SEC Story Brooke sold 2,300 shares
Director @ $81.42 ($187.3K)
LivaNova reported Q2 2026 revenue of $390.6M (+10.8% YoY) and adjusted diluted EPS of $1.26, beating consensus estimates
8-K — Impact 7/10
Aug 5, 2026 earnings_calendar
May 6, 2026 SEC LIVN Q2 2026 Earnings Before Market Open — 2026-08-05
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beating consensus of $346.
8-K — Impact 8/10
Analyst ratings buy % +6.6%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
81% rate it Buy or better · 16 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 2, 2026 | Piper Sandler | REITERATE | Overweight | 54% |
| Aug 5, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jul 15, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| Jul 1, 2026 | Freedom Capital Markets | INITIATE | Hold | 46% |
| Jun 22, 2026 | Keybanc | MAINTAIN | Overweight | 52% |
| May 7, 2026 | Barclays | MAINTAIN | Equal-Weight | 54% |
| May 7, 2026 | Mizuho | MAINTAIN | Outperform | 52% |
| May 7, 2026 | Baird | MAINTAIN | Outperform | 54% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Aug 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| Jul 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Jun 1, 2026 | 6 | 7 | 3 | 0 | 0 | 81% | |
| May 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Apr 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Mar 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% | |
| Feb 1, 2026 | 6 | 7 | 4 | 0 | 0 | 76% |
Price targets
Where 10 covering analysts think LIVN trades over the next 12 months.
$89.10 +18.7% upside Buy
Current$75.07 Low$75.00 Median$91.50 High$100.00 10 analysts
$75.00$100.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
50°
Neutral
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
5 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 5.2/10.
NEUTRALCLUSTER2/10
Two LivaNova directors sold a combined $460K in open-market sales over a one-week window, with Bianc
Sep 14, 2026
BULLISH8-K7/10
LivaNova reported Q2 2026 revenue of $390.6M (+10.8% YoY) and adjusted diluted EPS of $1.26, beating
Aug 5, 2026
BULLISH8-K8/10
LivaNova reported Q1 2026 revenue of $362.3M (+14.3% YoY reported, +11.1% constant-currency), beatin
May 6, 2026
NEUTRALDEFA14A2/10
LivaNova filed a definitive additional proxy soliciting material (DEFA14A) providing notice of its 2
Apr 29, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Aug 5, 2026
earnings_calendar
LIVN Q2 2026 Earnings Before Market Open — 2026-08-05
Aug 5, 2026
short_volume
Short Volume: LIVN — 65.9% short (0.5M / 0.8M)
Short: 524,897 | Exempt: 3,394 | TRF Vol: 796,535 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
Jul 14, 2026
ftd
FTD: LIVN — 14,260 shares ($1.2M) failed to deliver
Settlement: 20260714, Price: $82.98, FTD Value: $1,183,294.8, LIVANOVA PLC SHS (GBR)
Jun 30, 2026
ftd
FTD: LIVN — 39,003 shares ($3.2M) failed to deliver
Settlement: 20260630, Price: $83.06, FTD Value: $3,239,589.18, LIVANOVA PLC SHS (GBR)
Jun 29, 2026
ftd
FTD: LIVN — 65,403 shares ($5.5M) failed to deliver
Settlement: 20260629, Price: $83.43, FTD Value: $5,456,572.29, LIVANOVA PLC SHS (GBR)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $1.06 | $1.02–$1.13 | -4.8% | +0.2% | 2↑ 7↓ | $0.4B | 9 |
| Next Q | $1.06 | $1.03–$1.10 | 22.9% | -0.5% | 1↑ 8↓ | $0.4B | 9 |
| Current FY | $4.36 | $4.32–$4.40 | 11.7% | +0.3% | 9↑ 0↓ | $1.5B | 9 |
| Next FY | $4.68 | $4.46–$4.93 | 7.4% | -0.1% | 7↑ 1↓ | $1.6B | 9 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $1.057 | — |
| 7d ago | $1.057 | — |
| 30d ago | $1.054 | +0.002 |
| 60d ago | $1.081 | -0.024 |
| 90d ago | $1.081 | -0.024 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
14 insiders, 50 transactions. Net -$1.0M — $0.00 bought, $1.0M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Liddy Anne M. | Chief Legal Officer | AWARD | 6,291 | — | — |
| Sep 10, 2026 | Bianchi Francesco | Director | SELL | 3,500 | $78.01 | $273.0K |
| Sep 4, 2026 | Story Brooke | Director | SELL | 2,300 | $81.42 | $187.3K |
| Aug 31, 2026 | Bianchi Francesco | Director | SELL | 1,650 | $79.72 | $131.5K |
| Aug 11, 2026 | Tezel Ahmet | Chief Innovation Officer | D | 8,589 | $77.86 | $668.7K |
| Aug 11, 2026 | Tezel Ahmet | Chief Innovation Officer | EXERCISE | 12,692 | $52.68 | $668.6K |
| Aug 11, 2026 | Tezel Ahmet | Chief Innovation Officer | TAX W/H | 1,428 | $77.86 | $111.2K |
| Aug 11, 2026 | Tezel Ahmet | Chief Innovation Officer | SELL | 2,675 | $77.74 | $207.9K |
| Jun 15, 2026 | Bianchi Francesco | Director | EXERCISE | 4,042 | — | — |
| Jun 15, 2026 | PODLOGAR SUSAN M | Director | TAX W/H | 486 | $79.70 | $38.7K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for LIVN.
Shares short
5,375,448
Settlement Sep 15, 2026
Change vs prior
+7.8%
Semi-monthly cycle
Days to cover
9.7
At avg daily volume
Of shares outstanding
≈9.8%
Estimate — not % of float
All LIVN filing & press-release reports (5)
- CLUSTER reportSep 14, 2026
- 8-K reportAug 5, 2026
- 8-K reportMay 6, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportFeb 25, 2026